Essilor Luxottica's investment case is a balancing act, according to Bernstein analysts. While the eyecare titan saw a slight slowdown in sales growth, management is optimistic about prospects fueled by its AI smartglasses tie-up with Meta. Bernstein suggests this category will ensure a solid performance for the next year or two, but investors should watch for potential tech-driven disruption beyond that horizon, which could lead to share price volatility.

GSK's research-and-development plan is viewed positively, though Citi analysts suggest investors may wait for tangible results. The U.K. drugmaker aims for 1.9 billion pounds in annual cost savings by 2029 to fund its drug pipeline and enhance profitability. This includes a new R&D center in Cambridge, England, and accelerating development for seven drugs across 18 indications, doubling late-stage studies this year. Shares jumped 6% following the announcement.

Bernstein analysts also consider GSK's new R&D center in Cambridge a smart move, noting its proximity to a major AstraZeneca R&D hub and leading academic hospitals, which should boost R&D productivity through academic collaborations. GSK plans over 20 late-stage clinical trials to start this year and a three-year cost-cutting program to fund its late-stage portfolio. Shares rose 1.4%.